Results Expected in the Fourth Quarter This Year

Metavia, an affiliate of Dong-A ST, announced on April 13, 2026, that it has administered the first dose to a patient in Part 3 of Phase 1 clinical trials for 'DA-1726', a dual-acting GLP-1 (glucagon-like peptide) and glucagon obesity treatment currently under development in the United States as of April 10.


This Part 3 of Phase 1 clinical trial is designed to evaluate the safety and optimize the tolerability of high-dose administration using 'One-step' and 'Two-step' dose escalation strategies. It will be conducted over 16 weeks by dividing 40 healthy obese adults into two high-dose cohorts of 20 participants each.

Metavia Administers First Patient Dose in Part 3 of Phase 1 Clinical Trial for Dual-Acting Obesity Treatment View original image

Participants will be randomly assigned to the test and control groups at a 4:1 ratio. Part 3A will assess the 'One-step' escalation method, in which subjects take 16 mg for four weeks followed by 48 mg for 12 weeks. Part 3B will assess the 'Two-step' escalation method, in which subjects take 16 mg and 32 mg sequentially for four weeks each, followed by 64 mg for eight weeks. The study aims to comprehensively analyze not only the safety, tolerability, and pharmacokinetic characteristics of high-dose administration, but also its effects on metabolic indicators such as weight, waist circumference, and BMI (Body Mass Index).


Metavia aims to secure the data from Part 3 of the Phase 1 clinical trial of DA-1726 in the fourth quarter of this year.


DA-1726 is a novel drug candidate under development as an oxintomodulin analog-class obesity treatment. It acts simultaneously on GLP-1 and glucagon receptors to suppress appetite, promote insulin secretion, and increase basal metabolic rate in the periphery, ultimately leading to weight loss and improved blood sugar control.


In a previous additional Phase 1 clinical trial of DA-1726, Metavia confirmed an average weight reduction of 9.1% (9.6 kg) after eight weeks of administration, a decrease in waist circumference by 9.8 cm (3.8 inches), improvement in fasting glucose, and reduction in liver stiffness.


Hyungheon Kim, CEO of Metavia, stated, "With the first patient dosed in Part 3 of Phase 1, the development of DA-1726 has taken an important step forward," and added, "Through this trial, we will continue to validate the differentiated efficacy and potential of DA-1726."



Meanwhile, as the R&D hub of Dong-A Socio Group, Metavia is responsible for global research and development as well as commercialization, developing obesity treatment 'DA-1726', MASH treatment 'Vanoglifyl', and others. The company continues to introduce its competitiveness and growth strategies to global investors while actively seeking strategic partnership opportunities.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing